TLP
DFTX

Tri Locum Partners’s Definium Therapeutics DFTX Stock Holding History

Tri Locum Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.99M Buy
+369,588
New +$6.27M 0.98% 17
2025
Q1 		– Sell
-820,793
Closed -$5.71M – 32
2024
Q4 		$5.71M Sell
820,793
-842,160
-51% -$5.79M 1.18% 23
2024
Q3 		$9.46M Buy
1,662,953
+1,280,898
+335% +$8.91M 2.27% 15
2024
Q2 		$2.75M Buy
382,055
+2,459
+0.6% +$21.5K 0.7% 23
2024
Q1 		$3.57M Buy
+379,596
New +$2.16M 1.24% 25

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tri Locum Partners's DFTX Position: Q1 2026 in Review

Tri Locum Partners opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 369,588 shares worth $6.99M. The stake represents 0.98% of the portfolio and ranks #17 among its holdings. This is a return to the name: Tri Locum Partners previously reported a position in DFTX as recently as Q4 2024.

Tri Locum Partners first reported a position in DFTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $9.46M in Q3 2024. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Tri Locum Partners held 369,588 shares of Definium Therapeutics worth $6.99M as of Q1 2026.
  • Definium Therapeutics was a new Tri Locum Partners position in Q1 2026.
  • Definium Therapeutics made up 0.98% of Tri Locum Partners's portfolio in Q1 2026, its #17 holding.
  • Tri Locum Partners first reported a position in Definium Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Tri Locum Partners's Definium Therapeutics position peaked at $9.46M in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.